Figure 1.
Mean percentage change (95% CI) in MMS (MMS 5–7; MMS 8–9) at week 12 and week 52 (A) and at week 12 in pooled data from both ELEVATE UC 52 AND ELEVATE UC 12 stratified by biologic/JAKi-experience subgroups according to baseline MMS (B) (FAS). Bars represent 95% CIs. Abbreviations: CI, confidence interval; FAS, full analysis set; JAKi, Janus kinase inhibitor; MMS, modified Mayo score; N, number of patients in the full analysis set at the specified time point; n, number of patients with observations at a visit; UC, ulcerative colitis.

Mean percentage change (95% CI) in MMS (MMS 5–7; MMS 8–9) at week 12 and week 52 (A) and at week 12 in pooled data from both ELEVATE UC 52 AND ELEVATE UC 12 stratified by biologic/JAKi-experience subgroups according to baseline MMS (B) (FAS). Bars represent 95% CIs. Abbreviations: CI, confidence interval; FAS, full analysis set; JAKi, Janus kinase inhibitor; MMS, modified Mayo score; N, number of patients in the full analysis set at the specified time point; n, number of patients with observations at a visit; UC, ulcerative colitis.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close